Biologics Sales 2009: Antibodies are the growth drivers

Double digit growth rates in classes of antibodies and selected proteins

18-Mar-2010 - Spain

La Merie S.L. released the new compilation of biologics sales in 2009. In its fourth edition, the report showed again that cancer antibodies and anti-TNF antibodies were leading the field. Sales of insulins grew by 22.4% and consolidated its 3rd position in the ranking list due to the outstanding success of insulin analogs. The mature protein classes erythropoietins,G-CSF, interferon alpha, FSH and ERTs stagnated or even shrank. Sales of interferonbeta and coagulation factors grew with 13% and 16%, respectively.

Among the 28 blockbuster biologics with 2009 sales of more than US$ 1 bln, the ophthalmic antibodyLucentis achieved the highest growth rate (+33% vs 2008) followed by the multiplesclerosis antibody Tysabri (+30%) and the insulin analogs Lantus (+22.5%) and NovoLog/NovoRapid (+22%). Anti-inflammatory antibodies different from anti-TNF were newly introduced as a class of biologics due to their strong growth potential (+36.5% vs 2008).

Biosimilar sales reported by Sandoz (US$ 118 mln) had no impact on 2009biologics sales, but showed a growth rate of 73%. These results and more were found in an elaboration prepared by La Merie Business Intelligence and published in a complimentary report on March 12, 2010.

The document entitled “TOP 20 Biologics 2009” can be acquired as a free download.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous